Jouglar Emmanuel, de Marzi Ludovic, Verrelle Pierre, Créhange Gilles, Ferrand Regis, Doz François, Prezado Yolanda, Paoletti Xavier
Institut Curie, PSL Research University, Department of Radiation Oncology - Paris and Orsay Protontherapy Center, Paris, France.
Paris-Saclay University, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, Orsay, France.
Clin Transl Radiat Oncol. 2025 Feb 19;52:100932. doi: 10.1016/j.ctro.2025.100932. eCollection 2025 May.
The implementation and spread of new radiation therapy (RT) techniques are often rushed through before or without high-quality proof of a clinical benefit. The framework for phase 1, 2 and 3 trials, ideally designed for pharmaceutical evaluation, is not always appropriate for RT interventions. The IDEAL framework is a five-step process initially developed to enable the rapid implementation of surgical innovations while limiting risks for patients. IDEAL was subsequently adapted to RT. Proton-minibeam radiation therapy (pMBRT) is an innovative RT approach, using an array of parallel thin beams resulting in an outstanding increase in the therapeutic ratio. Cumulative preclinical evidence showed pMBRT was superior to standard RT regarding brain tolerance and provided equivalent or better local control in several glioblastoma models. We decided to adapt IDEAL to pMBRT to accelerate the implementation of this promising new technique in clinical care and present here some examples of possible upcoming studies.
新放射治疗(RT)技术的实施和推广往往在没有高质量临床获益证据之前或之时就仓促进行。用于药物评估的理想的1期、2期和3期试验框架并不总是适用于RT干预措施。IDEAL框架是一个五步流程,最初是为了在限制患者风险的同时实现手术创新的快速实施而开发的。IDEAL随后被应用于RT。质子微束放射治疗(pMBRT)是一种创新的RT方法,使用一系列平行细束,从而显著提高治疗比。累积的临床前证据表明,在脑耐受性方面,pMBRT优于标准RT,并且在几种胶质母细胞瘤模型中提供了同等或更好的局部控制。我们决定将IDEAL应用于pMBRT,以加速这一有前景的新技术在临床护理中的应用,并在此展示一些可能即将开展的研究示例。